Current Treatment of Schizoaffective Disorder According to a Neural NetworkFelix-Martin Werner1,2* and Rafael Covenas2
- *Corresponding Author:
- Felix-Martin Werner
Instituto de Neurociencias de Castilla y León (INCYL)
Laboratorio de Neuroanatomía de los Sistemas Peptidérgicos (Lab.14)
c/Pintor Fernando Gallego, 137007-Salamanca, Spain
Tel: +34/923/29 1856
Fax: +34/923/29 45 49
E-mail: [email protected]
Received Date: September 28, 2016; Accepted Date: December 02, 2016; Published Date: December 10, 2016
Citation: Werner FM, Covenas R (2016) Current Treatment of Schizoaffective Disorder According to a Neural Network. J Cytol Histol 7: 441. doi: 10.4172/2157-7099.1000441
Copyright: © 2016 Wern er FM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Schizoaffective disorder, which is combined with schizophrenic and affective, i.e. depressive or manic or alternating depressive and manic symptoms, has a prevalance of 0.5%. Here, we describe the alterations of the most important classical neurotransmitters in the brain regions involved in schizophrenic and affective symptoms. Schizoaffective is undoubtedly an inheritable chronic psychiatric disease, whereby traumata can enhance schizophrenic and affective symptoms in one third of patients. Neural networks are described in the brainstem, hippocampus and ventral tegmental area and the mentioned neurotransmitter alterations are considered. Prophylactic treatment of schizoaffective patients consists of administering mostly second-generation antipsychotic drugs alone or in combination with mood-stabilizing drugs. The clinical importance of the antipsychotic drug clozapine for a pharmacotherapy of treatment-resistant forms of the disease is underlined.